Current position

David Abrams’s Nuvation Bio Inc (NUVB) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Abrams Capital Management, L.P.Verified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ1 2021Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares3.81MHighest verified quarter-end share count
Quarters reported22Verified quarters with shares above zero
What happened?

Abrams Capital Management, L.P. first reported Nuvation Bio Inc in Q1 2021. The reported position was reduced across later filings. Abrams Capital Management, L.P. currently reports 1.27M shares. The latest verified filing showed: No change.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
No change1.27M shares reported
Filing context

Quarter-end price $5.68 · Estimated holding basis $8.92

Q1 2026
Sold 66.7% of the position−2.54M shares · 1.27M shares remained
Filing context

Quarter-end price $4.29 · Estimated holding basis $8.92

Q1 2021
New position+3.81M shares · 3.81M shares reported
Filing context

Quarter-end price $8.92 · Estimated holding basis $8.92

19 unchanged quarters are collapsed by default.

Portfolio importance

How important is Nuvation Bio Inc in Abrams Capital Management, L.P.’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.1%Q2 2026
Current rank#10of 11 reported positions
Peak portfolio weight0.8%Q3 2021
Best historical rank#10Q1 2026
At peak importanceQ3 2021
NUVB
0.8%
Largest holding
16.3%
Cross-investor discovery

Who else owns Nuvation Bio Inc?

Also reported by 3 other tracked investors in their latest verified filings.

Stanley DruckenmillerDuquesne Family Office
NUVB0.6% of reported portfolio
David EinhornDME Capital Management
NUVB0.0% of reported portfolio
Joel GreenblattGotham Asset Management
NUVB0.0% of reported portfolio
Explore Nuvation Bio Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$5.852026-09-18

Market context only; not an investor transaction price.

Latest filing quarter-end price$5.68Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$8.92Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-13
Open SEC filing ↗

This tracker follows Abrams Capital Management, L.P.’s Form 13F disclosures, not David Abrams’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.